GlassScriptPhysician profile
Nafisa D Burhani
NPI 1851386460
$16,867.54
in general payments reported to CMS, 2019-2025
91 companies · $2,884 in 2025
The $2,884 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $4,556 · 2021: $2,103 · 2022: $4,126 · 2023: $548 · 2024: $1,213 · 2025: $2,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749 · Long Term Medical Supply Or Device Loan: $698 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.71 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $197.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,906.27 | 2022-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $1,717.25 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,479.99 | 2020-2025 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Celgene Corporation | $1,116.76 | 2020-2025 | Reblozyl, Breyanzi, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $787.02 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $716.10 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $672.37 | 2019-2025 | Opdivo, Eliquis |
| Eisai INC. | $412.33 | 2019-2025 | |
| Lilly USA, LLC | $410.13 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Seagen INC. | $392.35 | 2019-2023 | |
| Genentech USA, INC. | $387.62 | 2019-2024 | Tecentriq Hybreza, Tecentriq, Itovebi |
| Janssen Biotech, INC. | $377.76 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Pfizer INC. | $343.12 | 2019-2025 | |
| Incyte Corporation | $287.60 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
Show all 82 companies
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nafisa Burhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.